切换至 "中华医学电子期刊资源库"

中华关节外科杂志(电子版) ›› 2024, Vol. 18 ›› Issue (01) : 125 -130. doi: 10.3877/cma.j.issn.1674-134X.2024.01.016

综述

噬菌体用于关节假体周围感染治疗的研究进展
杨友涵1, 文印宪1, 陈廖斌1,()   
  1. 1. 430071 武汉大学中南医院关节与运动医学科,武汉大学关节疾病研究中心
  • 收稿日期:2023-08-21 出版日期:2024-02-01
  • 通信作者: 陈廖斌

Research progress of bacteriophage in treatment of periprosthetic joint infection

Youhan Yang1, Yinxian Wen1, Liaobin Chen1,()   

  1. 1. Department of Joint and Sports Medicine, Zhongnan Hospital, Wuhan University, Joint Disease Research Center of Wuhan University, Wuhan 430071, China
  • Received:2023-08-21 Published:2024-02-01
  • Corresponding author: Liaobin Chen
引用本文:

杨友涵, 文印宪, 陈廖斌. 噬菌体用于关节假体周围感染治疗的研究进展[J/OL]. 中华关节外科杂志(电子版), 2024, 18(01): 125-130.

Youhan Yang, Yinxian Wen, Liaobin Chen. Research progress of bacteriophage in treatment of periprosthetic joint infection[J/OL]. Chinese Journal of Joint Surgery(Electronic Edition), 2024, 18(01): 125-130.

关节假体周围感染(PJI)是关节置换术后的严重并发症。药物治疗是目前PJI治疗的基础,但由于生物膜的屏障作用及耐药机制的存在,目前PJI的药物治疗效果仍不尽满意。近年来,噬菌体疗法受到越来越多人的关注,其在PJI治疗中的应用逐渐受到重视并涌现出一些新的研究思路和进展。噬菌体是自然存在的病毒,专门攻击和裂解细菌,对生物膜中的细菌也具有杀灭作用,且对细菌种类具有高度特异性而不影响人体微生物群。本文从生物膜的形成及耐药机制、噬菌体的生物类型及其杀菌机制、噬菌体对PJI的诊断作用、噬菌体治疗PJI的优势及限制以及噬菌体治疗PJI的临床进展等方面对噬菌体用于PJI治疗的研究进展进行综述,以求为PJI的治疗提供更多的启发。

Periprosthetic joint infection (PJI) is a serious complication after joint replacementsurgery. Drug therapy is the basis for the treatment of PJI. However, due to the barrier effect of biofilm and the existence of drug resistance mechanism, the current drug treatment effect of PJI is still not satisfactory. In recent years, bacteriophage therapy has drawn more and more attention. Its application in the treatment of PJI has gradually received attention and some new research ideas and progress have emerged. Bacteriophages are naturally occurring viruses that specifically attack and lyse bacteria. They also have a killing effect on bacteria in biofilms, and are highly specific to bacterial species without affecting human microflora. This article reviewed the research progress of bacteriophage in the treatment of PJI from the aspects of biofilm formation and drug resistance mechanism, bacteriophage biological type and its bactericidal mechanism, the diagnostic effect of bacteriophage on PJI, the advantages and limitations of bacteriophage in the treatment of PJI, and the clinical progress of phage in the treatment of PJI, in order to provide more inspiration for the treatment of PJI.

[1]
Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States[J]. J Arthroplasty, 2012, 27(8 Suppl): 61-65.e1.
[2]
Dale H, Fenstad AM, Hallan G, et al. Increasing risk of prosthetic joint infection after total hip arthroplasty[J]. Acta Orthop, 2012, 83(5): 449-458.
[3]
边焱焱,程开源,常晓,等. 2011至2019年中国人工髋膝关节置换手术量的初步统计与分析[J]. 中华骨科杂志2020, 40(21): 1453-1460.
[4]
Ferry T, Batailler C, Brosset S, et al. Medical innovations to maintain the function in patients with chronic PJI for whom explantation is not desirable: a pathophysiology-,multidisciplinary-,and experience-based approach[J/OL]. SICOT-J, 2020, 6: 26. DOI: 10.1051/sicotj/2020021.
[5]
Shoji MM, Chen AF. Biofilms in periprosthetic joint infections: areview of diagnostic modalities, current treatments, and future directions[J]. J Knee Surg, 2020, 33(2): 119-131.
[6]
Morris J, Kelly N, Elliott L, et al. Evaluation of bacteriophage anti-biofilm activity for potential control of orthopedic implant-related infections caused by Staphylococcus aureus[J]. Surg Infect, 2019, 20(1): 16-24.
[7]
Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases[J]. Nat Rev Microbiol, 2004, 2(2): 95-108.
[8]
Akanda ZZ, Taha M, Abdelbary H. Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections[J]. J Orthop Res, 2018, 36(4): 1051-1060.
[9]
Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections[J]. Science, 1999, 284(5418): 1318-1322.
[10]
Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms[J]. Int J Antimicrob Agents, 2010, 35(4): 322-332.
[11]
Bjarnsholt T, Ciofu O, Molin S, et al. Applying insights from biofilm biology to drug development - can a new approach be developed?[J]. Nat Rev Drug Discov, 2013, 12(10): 791-808.
[12]
Steadman W, Chapman PR, Schuetz M, et al. Local antibiotic delivery options in prosthetic joint infection[J/OL]. Antibiotics, 2023, 12(4): 752. DOI: 10.3390/antibiotics12040752.
[13]
Kim L. Persister cells[J]. Annu Rev Microbiol, 2010, 64: 357-372.
[14]
van Belleghem JD, Manasherob R, Międzybrodzki R, et al. The rationale for using bacteriophage to treat and prevent periprosthetic joint infections[J/OL]. Front Microbiol, 2020, 11: 591021. DOI: 10.3389/fmicb.2020.591021.
[15]
Doub JB, Urish K, Chan B. Bacteriophage therapy for periprosthetic joint infections: current limitations and research needed to advance this therapeutic[J]. J Orthop Res, 2023, 41(5): 1097-1104.
[16]
Gbejuade HO, Lovering AM, Webb JC. The role of microbial biofilms in prosthetic joint infections[J]. Acta Orthop, 2015, 86(2): 147-158.
[17]
Totten KMC, Patel R. Phage activity against planktonic and biofilm Staphylococcus aureusperiprostheticjoint infection isolates[J/OL]. Antimicrob Agents Chemother, 2022, 66(1): e0187921. DOI: 10.1128/AAC.01879-21.
[18]
Botka T, Pantůček R, Mašlaňová I, et al. Lytic and genomic properties of spontaneous host-range Kayvirus mutants prove their suitability for upgrading phage therapeutics against staphylococci[J/OL]. Sci Rep, 2019, 9(1): 5475. DOI: 10.1038/s41598-019-41868-w.
[19]
van BelleghemJD, D&#x;browska K, Vaneechoutte M, et al. Interactions between bacteriophage, bacteria, and the mammalian immune system[J/OL]. Viruses, 2018, 11(1): 10. DOI: 10.3390/v11010010.
[20]
Sosa BR, Niu Y, Turajane K, et al. 2020 John Charnley Award: the antimicrobial potential of bacteriophage-derived lysin in a murine debridement, antibiotics, and implant retention model of prosthetic joint infection[J]. Bone Joint J, 2020, 102-B(7_Supple_B): 3-10.
[21]
程永帅,刘炜洁,于腾波,等. 噬菌体裂解酶对兔膝关节假体周围感染的影响[J]. 中华实验外科杂志2018, 35(12): 2289-2291.
[22]
Gutiérrez D, Rodríguez-Rubio L, Martínez B, et al. Bacteriophages as weapons against bacterial biofilms in the food industry[J/OL]. Front Microbiol, 2016, 7: 825. DOI: 10.3389/fmicb.2016.00825.
[23]
Šuster K, Cör A. Induction of viable but non-culturable state in clinically relevant staphylococci and their detection with bacteriophage K[J/OL]. Antibiotics, 2023, 12(2): 311. DOI: 10.3390/antibiotics12020311.
[24]
Boyle KK, Wood S, Tarity TD. Low-virulence organisms and periprosthetic joint infection-biofilm considerations of these organisms[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 409-419.
[25]
Šuster K, Cör A. Fast and specific detection of staphylococcal PJI with bacteriophage-based methods within 104 sonicate fluid samples[J]. J Orthop Res, 2022, 40(6): 1358-1364.
[26]
Šuster K, Podgornik A, Cör A. An alternative molecular approach for rapid and specific detection of clinically relevant bacteria causing prosthetic joint infections with bacteriophage K[J]. New Microbiol, 2020, 43(3): 107-114.
[27]
Gemmel F, van den Wyngaert H, Love C, et al. Prosthetic joint infections: radionuclide state-of-the-art imaging[J]. Eur J Nucl Med Mol Imaging, 2012, 39(5): 892-909.
[28]
Jacqueline C, Caillon J. Impact of bacterial biofilm on the treatment of prosthetic joint infections[J]. J Antimicrob Chemother, 201469(Suppl 1): i37-i40.
[29]
Bruttin A, Brüssow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy[J]. Antimicrob Agents Chemother, 2005, 49(7): 2874-2878.
[30]
Hadas H, Einav M, Fishov I, et al. Bacteriophage T4 development depends on the physiology of its host Escherichia coli[J]. Microbiology, 1997143( Pt 1): 179-185.
[31]
Pearl S, Gabay C, Kishony R, et al. Nongenetic individuality in the host-phage interaction[J/OL]. PLoS Biol, 2008, 6(5): e120. DOI: 10.1371/journal.pbio.0060120.
[32]
Wright A, Hawkins CH, Anggård EE, et al. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy[J]. Clin Otolaryngol, 2009, 34(4): 349-357.
[33]
Ferry T, Leboucher G, Fevre C, et al. Salvage debridement, antibiotics and implant retention ( "DAIR" ) with local injection of a selected cocktail of bacteriophages: is it an option for an elderly patient with relapsing Staphylococcus aureusprosthetic-joint infection?[J/OL]. Open Forum Infect Dis, 2018, 5(11): ofy269. DOI: 10.1093/ofid/ofy269.
[34]
李朔,徐一宏,徐卫东. 人工关节置换术后感染的生物治疗方法及前景[J/CD]. 中华关节外科杂志(电子版), 2019, 13(2): 213-219.
[35]
van Belkum A, Gros MF, Ferry T, et al. Novel strategies to diagnose prosthetic or native bone and joint infections[J]. Expert Rev Anti Infect Ther, 2022, 20(3): 391-405.
[36]
DePalma BJ, Nandi S, Chaudhry W, et al. Assessment of staphylococcal clinical isolates from periprosthetic joint infections for potential bacteriophage therapy[J]. J Bone Joint Surg Am, 2022, 104(8): 693-699.
[37]
Donlan RM. Preventing biofilms of clinically relevant organisms using bacteriophage[J]. Trends Microbiol, 2009, 17(2): 66-72.
[38]
Łusiak-Szelachowska M, Zaczek M, Weber-Dąbrowska B, et al. Phage neutralization by sera of patients receiving phage therapy[J]. Viral Immunol, 2014, 27(6): 295-304.
[39]
Cano EJ, Caflisch KM, Bollyky PL, et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniaeinfection: case report and in vitrocharacterization of anti-biofilm activity[J/OL]. Clin Infect Dis, 2021, 73(1): e144-e151. DOI: 10.1093/cid/ciaa705.
[40]
Insall JN, Thompson FM, Brause BD. Two-stage reimplantation for the salvage of infected total knee arthroplasty. 1983[J/OL]. J Bone Joint Surg Am, 2002, 84(3): 490. DOI: 10.2106/00004623-200203000-00024.
[41]
Fedorov E, Samokhin A, Kozlova Y, et al. Short-term outcomes of phage-antibiotic combination treatment in adult patients with periprosthetic hip joint infection[J/OL]. Viruses, 2023, 15(2): 499. DOI: 10.3390/v15020499.
[42]
Ferry T, Kolenda C, Batailler C, et al. Case report: arthroscopic "debridement antibiotics and implant retention" with local injection of personalized phage therapy to salvage a relapsing Pseudomonas aeruginosaprostheticknee infection[J/OL]. Front Med, 2021, 8: 569159. DOI: 10.3389/fmed.2021.569159.
[43]
Cesta N, Pini M, Mulas T, et al. Application of phage therapy in a case of a chronic hip-prosthetic joint infection due to Pseudomonas aeruginosa: an Italian real-life experience and in vitroanalysis[J/OL]. Open Forum Infect Dis, 2023, 10(2): ofad051. DOI: 10.1093/ofid/ofad051.
[44]
Ferry T, Kolenda C, Gustave CA, et al. Phage therapy in bone and joint infection: history, scientific basis, feasibility and perspectives in France[J]. Virologie, 2020, 24(1): 49-56.
[45]
Taha M, Abdelbary H, Ross FP, et al. Newinnovations in the treatment of PJI and biofilms-clinical and preclinical topics[J]. Curr Rev Musculoskelet Med, 2018, 11(3): 380-388.
[46]
Morris JL, Letson HL, Elliott L, et al. Evaluation of bacteriophage as an adjunct therapy for treatment of peri-prosthetic joint infection caused by Staphylococcus aureus[J/OL]. PLoS One, 2019, 14(12): e0226574. DOI: 10.1371/journal.pone.0226574.
[47]
Kaur S, Harjai K, Chhibber S. In vivoassessment of phage and linezolid basedimplant coatings for treatment of methicillin resistant S. aureus (MRSA) mediated orthopaedicdevice related infections[J/OL]. PLoS One, 2016, 11(6): e0157626. DOI: 10.1371/journal.pone.0157626.
[1] 农云洁, 黄小桂, 黄裕兰, 农恒荣. 超声在多重肺部感染诊断中的临床应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 872-876.
[2] 刘欢, 邢皓, 常正奇, 张记. 机械敏感性离子通道蛋白Piezo1在感染相关疾病中的研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 263-269.
[3] 黄鸿初, 黄美容, 温丽红. 血液系统恶性肿瘤患者化疗后粒细胞缺乏感染的危险因素和风险预测模型[J/OL]. 中华实验和临床感染病杂志(电子版), 2024, 18(05): 285-292.
[4] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[5] 许月芳, 刘旺, 曾妙甜, 郭宇姝. 多粘菌素B和多粘菌素E治疗外科多重耐药菌感染临床疗效及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 700-703.
[6] 皮尔地瓦斯·麦麦提玉素甫, 李慧灵, 艾克拜尔·艾力, 李赞林, 王志, 克力木·阿不都热依木. 生物补片修补巨大复发性腹壁切口疝临床疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 624-628.
[7] 顾熙, 徐子宇, 周澍, 张吴楼, 张业鹏, 林昊, 刘宗航, 嵇振岭, 郑立锋. 腹股沟疝腹膜前间隙无张力修补术后补片感染10 例报道[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 665-669.
[8] 臧宇, 姚胜, 朱新勇, 戎世捧, 田智超. 低温等离子射频消融治疗腹壁疝术后补片感染的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 687-692.
[9] 杨闯, 马雪. 腹壁疝术后感染的危险因素分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 693-696.
[10] 胡菊英, 李银华, 洪兰, 王宏勇, 丁先军, 李承美, 谭心海. 儿童感染大叶性肺炎与支气管肺炎临床特征分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 813-816.
[11] 邢嘉翌, 龚佳晟, 祝佳佳, 陆群. 肺癌化疗患者继发肺部感染的病原菌耐药性及炎症因子变化分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 714-718.
[12] 中华医学会器官移植学分会. 肝移植术后缺血性胆道病变诊断与治疗中国实践指南[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 739-748.
[13] 丛黎, 马林, 陈旭, 李文文, 张亮亮, 周华亭. 改良CT严重指数联合炎症指标在重症急性胰腺炎患者胰腺感染预测及预后评估中的研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 432-436.
[14] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[15] 颜世锐, 熊辉. 感染性心内膜炎合并急性肾损伤患者的危险因素探索及死亡风险预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 618-624.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?